Clinical trials located in


Sheffield city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Sheffield, located in South Yorkshire, England, is renowned for its rich industrial heritage, particularly in steel production, earning it the nickname “Steel City.” This city is the birthplace of stainless steel and crucible steel, revolutionizing industries worldwide. Surrounded by the natural beauty of the Peak District National Park, Sheffield is one of the greenest cities in the UK, boasting numerous parks and woodland areas. It also has a vibrant cultural scene, with the iconic Sheffield Theatres complex and the annual Sheffield Doc/Fest attracting global attention.

  • CT-EU-00119402

    Study of infigratinib in children with achondroplasia

    The clinical study involves children with achondroplasia who previously participated in the PROPEL study. The study evaluates infigratinib, an oral tablet medication. The goal is to assess the safety, tolerance, and effectiveness of the drug. Infigratinib targets the fibroblast growth factor receptor (FGFR), which is crucial in processes like cell growth, wound healing, and bone and blood vessel formation.

    The study is aimed at children aged 3 to 11 years who can walk unaided and take oral medication. Various doses will be adjusted based on the child’s weight. The study will assess changes in annual height growth, pharmacokinetic parameters (such as maximum drug concentration in the blood), and any adverse events. Additionally, changes in body proportions, limb length, and other growth measures will be analyzed.

    • Infigratinib
  • Testing Vemurafenib and Cobimetinib for BRAF Positive Cancers

    This clinical trial is for patients with cancers that have a specific change in their cancer cells known as BRAF V600 mutation. It uses two drugs, vemurafenib and cobimetinib, to see if they can effectively treat various types of cancers such as solid tumors, haematological malignancies, melanoma, thyroid cancer, ovarian neoplasms, colorectal neoplasms, laryngeal neoplasms, non-small-cell lung carcinoma, glioma, multiple myeloma, and Erdheim-Chester disease. The purpose of this study is to determine if these drugs can help treat cancers with the BRAF V600 mutation.

    In the study, participants will receive both drugs until their disease progresses, they experience unacceptable side effects, or they decide to withdraw. Blood samples will be collected at different times during the treatment for research purposes. Participants will be monitored every three months for two years after completing the treatment.

    • Vemurafenib
    • Cobimetinib
  • Baricitinib study in children with juvenile idiopathic arthritis

    This clinical trial is designed to test whether Baricitinib is safe and effective in the treatment of systemic juvenile idiopathic arthritis in children aged 1 to 18 years. Participants will be assigned to one of two groups. In the first group, some participants will receive Baricitinib and others Tocilizumab as the reference drug. In the second group, all participants will receive Baricitinib.

    The primary objective of the study is to evaluate the percentage of participants who experience at least a 30% improvement in disease symptoms after 12 weeks of treatment according to the modified American College of Rheumatology Pediatric Response Criteria (PediACR30). Baricitinib is administered orally and Tocilizumab is administered by subcutaneous injection.

    • Tocilizumab
    • baricitinib
  • Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    • SCIB1 DNA vaccine
  • Tebentafusp for the treatment of recurrent melanoma

    The study aims to investigate a new treatment for patients with cutaneous melanoma or uveal melanoma after surgery. Researchers want to see if a new drug called tebentafusp can help these patients live longer.

    Tebentafusp is a new drug that has already been studied in patients with advanced melanoma of the skin and uvea. In this study, this medicine will be administered to patients whose disease has relapsed at the molecular level using a special blood test. Patients will receive tebentafusp for up to 6 months as an intravenous infusion once a week and will then be followed for 12 months to check whether the disease has returned.

    • tebentafusp
  • Treatment with Bel-Sar for patients with uveal melanoma

    The aim of this clinical trial is to test a new drug called Belzupacap Sarotalocan, or Bel-sar for short, for people with uveal melanoma.

    The main aim of this study is to test whether bel-sar is safe and effective compared to a dummy treatment, which acts as a placebo. The Bel-sar treatment involves injecting the drug (microinjection) into the eye space and then activating it with a special laser.

    The most important thing researchers want to know is how long it takes for the tumor to start growing again after treatment with bel-sar compared with sham treatment. They will closely monitor participants for up to 52 weeks to see how the situation progresses.

    • Placebo
    • Belzupacap Sarotalocan
  • Study on AOC 1020 for Facioscapulohumeral Muscular Dystrophy Treatment

    This study is aimed at exploring the safety, tolerability, and potential effectiveness of a novel treatment known as AOC 1020 for adults affected by Facioscapulohumeral Muscular Dystrophy (FSHD), covering both FSHD Type 1 and FSHD Type 2.

    The structure of the trial is randomized, double-blind, placebo-controlled, ensuring that participants are randomly allocated to receive either the AOC 1020 treatment or a placebo (a substance without therapeutic effect, serving as a control in the testing of new drugs) via an intravenous (IV) infusion. The objective is to keep both participants and study staff unaware of which treatment is being administered to maintain impartiality.

    The study consists of three stages. In Part A, appropriate doses of the drug are determined by administering single and multiple doses. Part B examines how the body responds to increasing doses of the drug. In Part C, participants receive different doses of the drug in parallel. The entire study lasts 12 months – 9 months is the treatment period, and then there is a 3-month observation period.

    After the conclusion of the active treatment and follow-up, participants are presented with the opportunity to enter a planned open-label extension, which allows continued access to the treatment being investigated. Those opting out of the extension are subjected to a 6-month safety follow-up period.

    The primary concern of the study is the monitoring of the incidence of treatment-emergent adverse events throughout the duration of the study, up to Day 365, to ensure the safety and well-being of all participants.

    • AOC 1020
  • A non-invasive test to assess adrenal function in children with asthma using inhaled steroids

    The study is focused on developing a new way to check whether the body is producing enough of an essential stress hormone called cortisol, especially in children using inhaled steroids to treat asthma. Steroid inhalers are common, but there is concern that they may prevent the body from producing enough cortisol when it is really needed, such as during illness. This could be serious. Currently, doctors use a test called the short synacten test (SST) to check whether the adrenal glands (which produce cortisol) are functioning properly. But this test requires needles and can be stressful and unpleasant, especially for children.

    The goal of the study is to create a non-invasive version of this test. Instead of needles, doctors want to use a nasal spray of a drug called Synacthen, which stimulates the adrenal glands, and then measure cortisol levels in saliva. This new method could make testing easier, faster and more convenient for children.

    Doctors will start by testing this new approach in adults to understand how well it works and how it compares to the traditional test. They will look at how the body absorbs the drug and how it affects cortisol levels. They will then perform the same tests on children to make sure it is safe and effective for them too.

    • nasal Tetracosactide
    • IV tetracosactide
  • A comprehensive evaluation of retatrutide in obesity and associated comorbidities

    This study evaluates the effectiveness and safety of a new drug, retatrutide, in individuals with obesity or overweight, including those with knee osteoarthritis or obstructive sleep apnea. Lasting about 89 weeks, the trial involves randomized assignment of participants to either receive retatrutide or a placebo. The main goals are to observe changes in body weight, knee pain in osteoarthritis, and sleep apnea severity. The study also examines various secondary outcomes like changes in BMI, waist circumference, and blood pressure. The trial aims to provide new insights into weight management and associated health conditions, offering hope for improved treatments.

    • Retatrutide
  • Testing safety and tolerability of a new Amyotrophic Lateral Sclerosis medication

    This study aims to assess the safety and tolerability of a novel medication, designated as QRL-201, in individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS). The drug is administered via intrathecal administration, directly into the cerebrospinal fluid surrounding the spinal cord. The study comprises 64 participants divided into 8 groups. Within each group of 8 individuals, 6 will receive the active medication, while 2 will receive a placebo, a substance with no therapeutic effect. The investigation includes the monitoring and reporting of any observed side effects or serious health events. Additionally, assessments will be conducted to measure the peak concentration of the critical drug in the bloodstream, the time taken to reach this peak concentration, and the overall quantity of the drug present in the bloodstream.

    • QRL-201
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    • macitentan
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    • gefurulimab/ALXN1720
  • Sotatercept treatment study for new Pulmonary Hypertension patients

    This study is an important test where doctors are looking at how a drug called Sotatercept can help people struggling with Pulmonary Arterial Hypertension (or PAH for short). The goal is to see whether this drug can delay or prevent the condition from getting worse. PAH makes it really hard for patients to breathe because it affects lungs and heart. The testing process is being done in a fair and careful way. Half of the patients will get the drug, and the others will get a ‘placebo’ which doesnt contain any medicine. The doctors will look at the effect on patients over time. The study is looking specifically at patients who were recently diagnosed with PAH and are at risk for the disease to get worse.

    • Sotatercept
  • Testing retatrutide’s effect on obesity and knee osteoarthritis

    This research is about a new medication called Retatrutide (LY3437943), which will be taken once a week by people who are overweight or suffer from obesity, and also have a condition where their knee hurts due to wear and tear, known as osteoarthritis of the knee. This is a third phase study, where we test how well the drug works and how safe it is. Unlike some studies, participants will not know whether they are taking the medication or a placebo (a pill that looks the same but doesn’t contain the medication). The study will last about 77 weeks.

    • Retatrutide
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    • Zamaglutenase/TAK-062
  • Fenfluramine Hydrochloride study for seizure control in cyclin-dependent kinase like-5 (CDKL5)

    This is studying a new substance called Fenfluramine Hydrochloride (ZX008) in children and adults experiencing seizures with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD). The research has two parts. In the first part, lasting 20 weeks, some participants receive the new drug, while others receive a placebo (inactive substance). This part aims to determine if ZX008 is effective and safe. The second part lasts 54 weeks and is open-label, meaning everyone is aware they are receiving the active drug. It helps assess long-term effects. If participants complete the first part, they can enroll in the second part, including an open-label treatment period (52 weeks) and a taper period (2 weeks).

    • Fenfluramine Hydrochloride/ZX008
  • Study on treating uncontrolled bleeding with bentracimab

    A trial investigating bentracimab’s ability to reverse ticagrelor’s effects in patients with severe bleeding or those needing urgent surgery. The study, involving at least 200 patients from various regions, tests if bentracimab can quickly counteract ticagrelor, improving patients’ conditions or allowing for safe surgeries. Patients receive a thorough follow-up to ensure the drug’s effectiveness and safety, aiming to provide a reliable treatment for critical, time-sensitive medical scenarios.

    • bentracimab/PB2452
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Testing bemarituzumab treatment on solid tumors

    This study is testing a new drug, bemarituzumab, for people with certain advanced solid tumors that are high in a protein called FGFR2b. It is for adults whose cancer has not responded to previous treatment or cannot be surgically removed. The main goal of this test is to see if bemarituzumab can help fight these cancers and to make sure it is safe for people to take. Participants receive the drug through a drip. This study will use special imaging methods, such as computed tomography or magnetic resonance imaging, to see how the tumors respond to the drug. If the drug helps and the tumor shrinks or doesn’t grow, researchers will track how long it lasts.

    • Bemarituzumab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil

See more clinical trials in other cities in United Kingdom: